Abstract Details

Title Why Are Patients Excluded from Intravenous Alteplase Therapy after Acute Ischemic Stroke? The University of California, San Diego Experience

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) (-)

Poster/Presentation
Number 057

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Nhu T. Bruce, MD (Houston Methodist)	No disclosure on file
Rema Raman, PhD	No disclosure on file
	No disclosure on file
Thomas M. Hemmen, MD, PhD (University of California, San Diego)	Dr. Hemmen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck & Co. Dr. Hemmen has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. The institution of Dr. Hemmen has received research support from NIH.
Fen Bao	Fen Bao has nothing to disclose.

��ɫ��